Non Small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors
Verified date | June 2024 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to evaluate the safety and efficacy (how well the study drug works against the disease) of ABBV-637 alone or in combination with docetaxel/osimertinib in participants with solid tumors (NSCLC). Adverse events and change in disease activity will be assessed. ABBV-637 is an investigational drug being developed for the treatment of solid tumors. Study consists of 3 parts - monotherapy dose escalation (Part 1), combination dose escalation and expansion (Parts 2a and 2b) with docetaxel and combination dose escalation and expansion (Parts 3a and 3b) with osimertinib. Approximately 109 adult participants with relapsed/refractory (R/R) solid tumors will be enrolled in approximately 30 sites across the world. In Part 1, participants with solid tumors will receive intravenous (IV) ABBV-637 in 28-day cycles. In Part 2a and 2b, participants will receive IV ABBV-637 in combination with IV docetaxel in 28-day cycles. In Part 3a and 3b, participants will receive intravenous (IV) ABBV-637 in combination with daily oral tablets of osimertinib in 28-day cycle. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. Treatment effects will be monitored by medical assessments, blood tests, side effect reporting, and questionnaires.
Status | Active, not recruiting |
Enrollment | 81 |
Est. completion date | August 30, 2024 |
Est. primary completion date | August 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologic solid tumor diagnosis (Part 1). - For Part 2 docetaxel combination therapy: EGFR WT expressing relapsed/refractory (R/R) non-small cell lung cancer (NSCLC) participants. - For Part 3 osimertinib combination therapy: mutEGFR-expressing RR NSCLC participants. - Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. - For Part 1 only - history of R/R disease that has progressed on all standard of care therapy. - For Part 2 only - history of RR NSCLC that has progressed after treatment with platinum-based chemotherapy regimen and either immune checkpoint inhibitor or targeted therapy and may not have been treated with prior single agent chemotherapy. - For Part 3 only - history of RR NSCLC that has progressed on osimertinib - Meet the laboratory values as described in the protocol. Exclusion Criteria: - History (within 6 months) of congestive heart failure (defined as New York Heart Association, Class 2 or higher), ischemic cardiovascular event, cardiac arrhythmia requiring pharmacological or surgical intervention, pericardial effusion, or pericarditis. - Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia. - For Part 3 only: History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, nor any evidence of active ILD or pneumonitis. |
Country | Name | City | State |
---|---|---|---|
Australia | Austin Health /ID# 225638 | Heidelberg | Victoria |
Australia | Wollongong Hospital /ID# 228350 | Wollongong | New South Wales |
France | Institut Bergonie /ID# 225778 | Bordeaux | Gironde |
France | Centre Georges François Leclerc /ID# 226760 | Dijon | |
France | AP-HM - Hopital de la Timone /ID# 225779 | Marseille CEDEX 05 | Bouches-du-Rhone |
France | Institut Curie /ID# 225829 | Paris CEDEX 05 | Paris |
France | Institut Claudius Regaud /ID# 225780 | Toulouse | |
Israel | Rambam Health Care Campus /ID# 225586 | Haifa | H_efa |
Israel | The Chaim Sheba Medical Center /ID# 225585 | Ramat Gan | Tel-Aviv |
Japan | National Cancer Center Hospital /ID# 225724 | Chuo-ku | Tokyo |
Japan | National Hospital Organization Kyushu Cancer Center /ID# 240761 | Fukuoka-shi | Fukuoka |
Japan | National Cancer Center Hospital East /ID# 225725 | Kashiwa-shi | Chiba |
Japan | National Hospital Organization Shikoku Cancer Center /ID# 240821 | Matsuyama-shi | Ehime |
Japan | NHO Nagoya Medical Center /ID# 244412 | Nagoya-shi | Aichi |
Korea, Republic of | National Cancer Center /ID# 231887 | Goyang-si | Gyeonggido |
Korea, Republic of | Asan Medical Center /ID# 231886 | Seoul | Seoul Teugbyeolsi |
Korea, Republic of | Samsung Medical Center /ID# 231888 | Seoul | |
Korea, Republic of | Yonsei University Health System Severance Hospital /ID# 233774 | Seoul | Seoul Teugbyeolsi |
Spain | Hospital Universitario Vall d'Hebron /ID# 225976 | Barcelona | |
Spain | Hospital Universitario 12 de Octubre /ID# 225977 | Madrid | |
Spain | Hospital Universitario Fundacion Jimenez Diaz /ID# 225975 | Madrid | |
Spain | Hospital Universitario Puerta de Hierro - Majadahonda /ID# 226096 | Majadahonda | Madrid |
Spain | Hospital Universitario Virgen de la Victoria /ID# 225978 | Malaga | |
Taiwan | National Taiwan University Hospital - Hsinchu branch /ID# 243610 | Hsinchu City | |
Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 243345 | Kaohsiung | |
Taiwan | National Cheng Kung University Hospital /ID# 225944 | Tainan | |
Taiwan | Linkou Chang Gung Memorial Hospital /ID# 225946 | Taoyuan City | |
United States | Dana-Farber Cancer Institute /ID# 231209 | Boston | Massachusetts |
United States | Virginia Cancer Specialists - Fairfax /ID# 225693 | Fairfax | Virginia |
United States | Carolina BioOncology Institute /ID# 225358 | Huntersville | North Carolina |
United States | Lifespan Cancer Institute at Rhode Island Hospital /ID# 226145 | Providence | Rhode Island |
United States | Washington University-School of Medicine /ID# 225698 | Saint Louis | Missouri |
United States | South Texas Accelerated Research Therapeutics /ID# 225359 | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Experiencing Adverse Events (AEs) | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. | Up to approximately 3 years | |
Primary | Percentage of Participants With Objective Response Rate (ORR) (Part 2 & 3) | ORR is defined as the percentage of participants with a confirmed response (CR) or partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. | Up to approximately 3 years | |
Secondary | Percentage of Participants With Objective Response Rate (ORR) (Part 1) | ORR is defined as the percentage of participants with a confirmed response (CR) or partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. | Up to approximately 3 years | |
Secondary | Duration of Response (DOR) for ABBV-637 Administered as Monotherapy (Part 1) | DOR is defined as the time from the initial response of CR/PR per investigator review according to RECIST version 1.1 criteria to the first occurrence of radiographic disease progression, clinical progression or death from any cause whichever occurs first. | Up to approximately 12 months | |
Secondary | Duration of Response (DOR) for ABBV-637 in Combination With Docetaxel and Osimertinib (Part 2 & 3) | DOR is defined as the time from the initial response of CR/PR per investigator review according to RECIST version 1.1 criteria to the first occurrence of radiographic disease progression, clinical progression or death from any cause whichever occurs first. | Up to approximately 20 months | |
Secondary | Progression-Free Survival (PFS) for ABBV-637 in Combination With Docetaxel and Osimertinib (Part 2 & 3) | PFS is defined as the time from the first dose of any study drug to a documented radiographic disease progression according to RECIST version 1.1 as determined by the investigator, clinical progression or death from any cause, whichever occurs earlier. | Up to approximately 20 months | |
Secondary | Overall Survival (OS) for ABBV-637 in Combination With Docetaxel and Osimertinib (Part 2 & 3) | OS is defined as the time from the first dose of any study drug until death from any cause. | Up to approximately 12 months after last dose of study drug |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01204099 -
Study of PX-866 and Docetaxel in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00148798 -
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
|
Phase 3 | |
Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02988817 -
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01005797 -
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
|
Phase 1 | |
Recruiting |
NCT00637910 -
Tarceva Italian Lung Optimization tRial
|
Phase 3 | |
Active, not recruiting |
NCT03447678 -
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
|
Phase 2 | |
Completed |
NCT02456246 -
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
|
N/A | |
Completed |
NCT02014324 -
Single Scope Staging of Lung Cancer With Endosonography
|
N/A | |
Terminated |
NCT01741155 -
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01594398 -
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01323062 -
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04772989 -
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01702844 -
Single Arm on the Tolerability of Weekly Nab-paclitaxel
|
Phase 2 | |
Completed |
NCT00492206 -
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
|
Phase 2 | |
Completed |
NCT00820417 -
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
|
Phase 1 | |
Completed |
NCT02639026 -
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
|
Phase 1 | |
Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
Not yet recruiting |
NCT05473156 -
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
|
Phase 1/Phase 2 |